Last checked at 9 Mar 2015 07:00
Proteome Sciences plc
("Proteome" or the "Company")
Trading update
9 March 2015: The Board is pleased to announce that its biomarker services division has got off to a good start in 2015 with five biomarker contracts signed. Encouragingly, there has been a strong increase in demand for SysQuant® , TMT® calibrator and TMT® MS3 services from major pharmaceutical customers and this is reflected by a growing pipeline of firm orders and quotations that should close in Q1/Q2.
The CK1d marketing dossier to outlicense our 2 compounds against tau aggregation in Alzheimer's disease which were completed and dispatched in December have received very positive feedback from a broad cross section of pharmaceutical companies with non-disclosure agreements (NDA) signed and now in place. We intend to continue to move that process along and keep shareholders updated with further developments. We have experienced similar engagement and interest in the MCI/AD blood biomarker panel with a number of major diagnostics companies and we are actively advancing the licensing programme under NDA. In both AD licensing programmes, we have been able to successfully cross-market SysQuant® and TMT® calibrator services with prospective licensees who have been highly impressed with the quality of the data and we believe that this should lead to a number of additional biomarker services contracts.
We were pleased to receive notification of the issuance from the US Patent Office of US 8,822,171B1 Methods of Screening Inhibitors of Tau Phosphorylation by Casein Kinase 1. The issuance further expands Proteome Sciences' IP in AD, particularly the tau pathway and provides additional support to our licensing discussions.
Our core activities including TMT® are performing well and we expect to see this reflected through solid growth in revenue and news flow in 2015 with further visibility from our licensing activities.
- Ends -
For further information please contact:
Proteome Sciences plc | |
Christopher Pearce, Executive Chairman | |
Dr. Ian Pike, Chief Operating Officer | Tel: +44 (0)1932 865065 |
Geoff Ellis, Finance Director | |
Nominated Adviser | |
Cenkos | |
Mark Connelly/Callum Davidson finnCap Geoff Nash | Tel: +44 (0)20 7397 8900
Tel : +44 (0)20 7220 0563 |
Public Relations | |
IKON Associates | Email: adrian@ikonassociates.com |
Adrian Shaw | Tel: +44 (0)1483 271291 |
Mobile +44(0)7979 900733 | |
Notes for editors:
About Proteome Sciences plc (www.proteomics.com)
Proteome Sciences is a global leader in applied proteomics and peptidomics offering high sensitivity, proprietary technologies for protein and peptide biomarker discovery, validation and assay development. The Company is headquartered in Cobham, UK, with laboratory facilities in London and Frankfurt.
Proteome Sciences' proprietary research has discovered a large number of novel protein biomarkers in key human diseases and is focused mainly in neurological/neurodegenerative conditions and in cancer. It has discovered and patented blood biomarkers in Alzheimer's disease, stroke, brain damage and lung cancer for diagnostic and treatment applications that are available for license or have already been outlicensed.
The Company's PS Biomarker Services™ division provides outsourced proteomics services and proprietary biomarker assays to pharmaceutical, biotechnology and diagnostics companies from its ISO 9001: 2008 facility in Frankfurt, Germany.